Celcuity Sees Bright Future Ahead as Gedatolisib Nears FDA Approval
Celcuity, a biotechnology company focused on developing innovative treatments for various types of cancer, has made significant strides in its mission to revolutionize the field of oncology. In a recent conference call, Celcuity's leadership team presented the company's Q4 2025 financial results and business update, highlighting several key milestones that position the company for a transformative year ahead.
One of the most notable developments was the FDA's acceptance of Celcuity's new drug application (NDA) for its lead product candidate, gedatolisib. The NDA has been granted priority review with a Prescription Drug User Fee Act (PDUFA) goal date of July 17th, 2026. This is a significant accomplishment, as the FDA's Real-Time Oncology Review Program is utilized for drugs offering substantial improvements over available therapies.
The data from the PIK3CA wild-type cohort of the phase III VIKTORIA-1 clinical trial have been nothing short of remarkable. The median progression-free survival (PFS) for the gedatolisib triplet was 9.3 months, compared to only two months for fulvestrant. This represents a significant improvement in treatment outcomes for patients with HR-positive, HER2-negative advanced breast cancer.
"We're optimistic about the outcome of the FDA's review of our NDA," said Brian Sullivan, Celcuity's CEO and Co-founder. "The unprecedented efficacy data from the PIK3CA wild-type cohort of the VIKTORIA-1 trial sets several new benchmarks for clinical trials evaluating patients in this disease setting."
Additionally, Celcuity has completed enrollment of the PIK3CA mutant cohort of its phase III VIKTORIA-1 trial. Reporting results from this cohort will be another significant milestone for the company, with top-line press release expected in the second quarter and full results to be presented at a medical conference in 2026.
The company's financial performance has also been noteworthy, with a number of clinical and regulatory milestones achieved while significantly bolstering its balance sheet. As Celcuity prepares for the potential approval and commercialization of gedatolisib, investors are eager to see how this new standard of care therapy will be received by the market.
With a strong foundation in place, Celcuity is poised for a transformative year ahead. The company's leadership team has demonstrated their ability to navigate the complexities of drug development and regulatory approval, and investors would do well to keep a close eye on this promising biotech company as it continues to make waves in the oncology space.
